2026-04-18T06:23:32Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4681172026-03-28T08:39:39Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Benitez Amaro, Aleyda author Martínez-Bosch, Neus author Manero-Rupérez, Noemí author Claudi, Lene author La Chica Lhoëst, María Teresa author Soler Castany, Marta author Ros-Blanco, Lia author Navarro, Pilar author Llorente-Cortés, Vicenta author 2022 Altres ajuts: Fundación BBVA Convocatoria Ayudas a Equipos de Investigación Científica Fundación BBVA 2019; Fondo Europeo de Desarrollo Regional (FEDER); Ministerio de Asuntos Económicos y Transformación Digital, RED2018-102799-T Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). LDL aggregation can be efficiently inhibited by low-density lipoprotein receptor-related protein 1 (LRP1)-based peptides. The objectives of this work were: (i) to determine if aggregated LDLs affect the intracellular cholesteryl ester (CE)/free cholesterol (FC) ratio and/or the tumor pancreatic cell proliferation, using sphingomyelinase-modified LDL particles (Aggregated LDL, AgLDL); and (ii) to test whether LRP1-based peptides, highly efficient against LDL aggregation, can interfere in these processes. For this, we exposed human pancreatic cancer cell lines (PANC-1, RWP-1 and Capan-1) to native (nLDL) or AgLDLs in the absence or presence of LRP1-based peptides (DP3) or irrelevant peptides (IP321). Results of thin-layer chromatography (TLC) following lipid extraction indicate that AgLDLs induce a higher intracellular CE/FC ratio than nLDL, and that DP3 but not IP321 counteracts this effect. AgLDLs also increase PANC-1 cell proliferation, which is inhibited by the DP3 peptide. Our results indicate that AgLDL-induced intracellular CE accumulation plays a crucial role in the proliferation of pancreatic tumor cell lines. Peptides with anti-LDL aggregation properties may thus exhibit anti-tumor effects. Anti-LDL aggregation peptides LDL atherogenicity Cholesteryl esters Pancreatic ductal adenocarcinoma Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells